Brown Advisory Securities LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 3.9% during the first quarter, Holdings Channel reports. The fund owned 8,050 shares of the company’s stock after buying an additional 301 shares during the period. Brown Advisory Securities LLC’s holdings in Eli Lilly and were worth $678,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. First Command Financial Services Inc. increased its position in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co purchased a new position in shares of Eli Lilly and during the first quarter valued at about $135,000. Penserra Capital Management LLC increased its position in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares in the last quarter. Crestwood Advisors Group LLC purchased a new position in shares of Eli Lilly and during the first quarter valued at about $179,000. Finally, Sandy Spring Bank increased its position in shares of Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock valued at $185,000 after buying an additional 750 shares in the last quarter. 75.61% of the stock is owned by institutional investors.

Shares of Eli Lilly and Company (NYSE LLY) traded up 0.02% on Friday, reaching $81.55. 601,093 shares of the company’s stock were exchanged. The stock has a market cap of $86.04 billion, a P/E ratio of 35.29 and a beta of 0.34. The company’s 50 day moving average price is $83.00 and its 200-day moving average price is $81.69. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.86 EPS. Equities analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.

TRADEMARK VIOLATION NOTICE: “Brown Advisory Securities LLC Has $678,000 Stake in Eli Lilly and Company (LLY)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/brown-advisory-securities-llc-has-678000-stake-in-eli-lilly-and-company-lly.html.

LLY has been the subject of several analyst reports. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $92.00 price target on shares of Eli Lilly and in a report on Tuesday, May 16th. BMO Capital Markets set a $71.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. Credit Suisse Group reissued an “outperform” rating and set a $87.00 price target on shares of Eli Lilly and in a report on Wednesday, April 19th. Finally, Argus downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating and lifted their price target for the company from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $88.27.

In related news, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock worth $55,845,287 over the last quarter. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.